Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Needs "Public Face" To Improve Reach Of Safety Communications, Cmte. Says

Executive Summary

FDA could enhance its stature as a source of product safety information if it put a public face on its risk communications. Christine Bruhn, University of California-Davis, suggested during the advisory panel meeting.

You may also be interested in...



FDA Tracking Tweets, Blog Posts To Gauge Reach Of Drug Safety Communications

FDA is in the early stages of developing a plan for how to get the most dissemination bang for its risk communication bucks.

FDA Tracking Tweets, Blog Posts To Gauge Reach Of Drug Safety Communications

FDA is in the early stages of developing a plan for how to get the most dissemination bang for its risk communication bucks.

No contest for FDA public relations

The House Energy and Commerce Committee calls an FDA campaign to improve its public image "a reckless use of taxpayer dollars." The panel is investigating the award of a sole source contract for the public relations initiative to its probe of "administrative integrity" at the agency. More serious than the campaign's waste of precious resources are "the numerous violations of federal procurement and contracting laws that appear to have occurred," the committee tells HHS Secretary Michael Leavitt in an Oct. 2 letter. The small business designation of Alaska Newspapers, Inc., which was selected to direct the PR campaign, allowed the $300,000 contract to be let without going out to bid. Alaska Newspapers subcontracted the work to Qorvis Communications, which has done PR work for the trade group Pharmaceutical Research and Manufacturers of America. A review of records supplied by the agency in August "suggests that FDA and Qorvis worked together to intentionally circumvent federal contracting regulations," the committee contends. FDA, which has put a hold on all activities under the contract, says Alaska Newspapers certified it would perform at least 51 percent of the work, but an independent investigation was requested Sept. 22

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel